These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 29302674)
1. Mechanical stiffening of human rhinovirus by cavity-filling antiviral drugs. Valbuena A; Rodríguez-Huete A; Mateu MG Nanoscale; 2018 Jan; 10(3):1440-1452. PubMed ID: 29302674 [TBL] [Abstract][Full Text] [Related]
2. Molecular Determinants of Human Rhinovirus Infection, Assembly, and Conformational Stability at Capsid Protein Interfaces. Valiente L; López-Argüello S; Rodríguez-Huete A; Valbuena A; Mateu MG J Virol; 2022 Dec; 96(23):e0084022. PubMed ID: 36374110 [TBL] [Abstract][Full Text] [Related]
3. The pentamer channel stiffening model for drug action on human rhinovirus HRV-1A. Vaidehi N; Goddard WA Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2466-71. PubMed ID: 9122218 [TBL] [Abstract][Full Text] [Related]
4. Single-Molecule Analysis of Genome Uncoating from Individual Human Rhinovirus Particles, and Modulation by Antiviral Drugs. Valbuena A; Strobl K; Gil-Redondo JC; Valiente L; de Pablo PJ; Mateu MG Small; 2024 Feb; 20(6):e2304722. PubMed ID: 37806749 [TBL] [Abstract][Full Text] [Related]
5. Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation. Ninomiya Y; Ohsawa C; Aoyama M; Umeda I; Suhara Y; Ishitsuka H Virology; 1984 Apr; 134(2):269-76. PubMed ID: 6100571 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of novel chloropyridazine derivatives as potent human rhinovirus (HRV) capsid-binding inhibitors. Fan SY; Zheng ZB; Mi CL; Zhou XB; Yan H; Gong ZH; Li S Bioorg Med Chem; 2009 Jan; 17(2):621-4. PubMed ID: 19091578 [TBL] [Abstract][Full Text] [Related]
7. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14. Shepard DA; Heinz BA; Rueckert RR J Virol; 1993 Apr; 67(4):2245-54. PubMed ID: 8383239 [TBL] [Abstract][Full Text] [Related]
8. Long-distance correlations of rhinovirus capsid dynamics contribute to uncoating and antiviral activity. Roy A; Post CB Proc Natl Acad Sci U S A; 2012 Apr; 109(14):5271-6. PubMed ID: 22440750 [TBL] [Abstract][Full Text] [Related]
9. The structure of human rhinovirus 16. Oliveira MA; Zhao R; Lee WM; Kremer MJ; Minor I; Rueckert RR; Diana GD; Pevear DC; Dutko FJ; McKinlay MA Structure; 1993 Sep; 1(1):51-68. PubMed ID: 7915182 [TBL] [Abstract][Full Text] [Related]
10. Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activation. Kim SR; Song JH; Ahn JH; Lee GS; Ahn H; Yoon SI; Kang SG; Kim PH; Jeon SM; Choi EJ; Shin S; Cha Y; Cho S; Kim DE; Chang SY; Ko HJ Antiviral Res; 2018 Mar; 151():87-96. PubMed ID: 29407486 [TBL] [Abstract][Full Text] [Related]
11. Amino Acid Side Chains Buried along Intersubunit Interfaces in a Viral Capsid Preserve Low Mechanical Stiffness Associated with Virus Infectivity. Carrillo PJ; Medrano M; Valbuena A; Rodríguez-Huete A; Castellanos M; Pérez R; Mateu MG ACS Nano; 2017 Feb; 11(2):2194-2208. PubMed ID: 28117975 [TBL] [Abstract][Full Text] [Related]
12. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides. Ninomiya Y; Shimma N; Ishitsuka H Antiviral Res; 1990 Feb; 13(2):61-74. PubMed ID: 2160796 [TBL] [Abstract][Full Text] [Related]
13. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Grant RA; Hiremath CN; Filman DJ; Syed R; Andries K; Hogle JM Curr Biol; 1994 Sep; 4(9):784-97. PubMed ID: 7820548 [TBL] [Abstract][Full Text] [Related]
14. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Rollinger JM; Schmidtke M Med Res Rev; 2011 Jan; 31(1):42-92. PubMed ID: 19714577 [TBL] [Abstract][Full Text] [Related]
15. VP4 protein from human rhinovirus 14 is released by pressure and locked in the capsid by the antiviral compound WIN. Gonçalves RB; Mendes YS; Soares MR; Katpally U; Smith TJ; Silva JL; Oliveira AC J Mol Biol; 2007 Feb; 366(1):295-306. PubMed ID: 17161425 [TBL] [Abstract][Full Text] [Related]
16. A novel benzonitrile analogue inhibits rhinovirus replication. Lacroix C; Querol-Audí J; Roche M; Franco D; Froeyen M; Guerra P; Terme T; Vanelle P; Verdaguer N; Neyts J; Leyssen P J Antimicrob Chemother; 2014 Oct; 69(10):2723-32. PubMed ID: 24948704 [TBL] [Abstract][Full Text] [Related]
17. Structural basis for biologically relevant mechanical stiffening of a virus capsid by cavity-creating or spacefilling mutations. Guerra P; Valbuena A; Querol-Audí J; Silva C; Castellanos M; Rodríguez-Huete A; Garriga D; Mateu MG; Verdaguer N Sci Rep; 2017 Jun; 7(1):4101. PubMed ID: 28642465 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and anti-rhinovirus activity of novel 3-[2-(pyridinyl)vinyl]substituted -2H-chromenes and -4H-chromen-4-ones. Conti C; Proietti Monaco L; Desideri N Bioorg Med Chem; 2014 Feb; 22(3):1201-7. PubMed ID: 24360829 [TBL] [Abstract][Full Text] [Related]
19. Development of a high-throughput human rhinovirus infectivity cell-based assay for identifying antiviral compounds. Phillips T; Jenkinson L; McCrae C; Thong B; Unitt J J Virol Methods; 2011 May; 173(2):182-8. PubMed ID: 21300110 [TBL] [Abstract][Full Text] [Related]
20. The structure of antiviral agents that inhibit uncoating when complexed with viral capsids. Rossmann MG Antiviral Res; 1989 Feb; 11(1):3-13. PubMed ID: 2540708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]